Table 4.
Clinical parameters of CD patients.
| CD | No. | Gender | Age | CDAI | BM | QOL | |||
|---|---|---|---|---|---|---|---|---|---|
| M/F | Visit 1 | Visit 3 | Visit 1 | Visit 3 | Visit 1 | Visit 3 | |||
| Cannabis | 13 | 6/7 | 34 ± 15 | 278 ± 22 | 171 ± 30.7* | 5.6 ± 0.78 | 3.7 ± 0.8* | 75 ± 5.7 | 94.2 ± 5.2* |
| Placebo | 17 | 8/9 | 35 ± 9 | 309 ± 27 | 236 ± 26.7* | 6.8 ± 1.18 | 4.1 ± 0.8* | 74.5 ± 4.48 | 72.5 ± 5.8^ |
CDAI score and BM and QOL levels in CD patients before and after cannabis/placebo use: CD patients were treated for 8 weeks with cannabis or placebo. At time 0 (visit 1) and 8 weeks following the cannabis or placebo use (visit 3), CDAI score, BM, and QOL levels were evaluated.
*Results significantly different from visit 1 (p < 0.05).
^Results significantly different between the placebo to the cannabis group (p < 0.05).